Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

27 déc. 2018 07h30 HE | Source: BeyondSpring, Inc.

BeyondSpring Announces Positive Pre-NDA Meeting with the U.S. FDA for its Lead Asset, Plinabulin

NEW YORK, Dec. 27, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it...
21 déc. 2018 07h30 HE | Source: BeyondSpring, Inc.

United States Patent and Trademark Office Issues Composition of Matter Patent with BeyondSpring’s Lead Asset Plinabulin with Protection to 2036

NEW YORK, Dec. 21, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the...
06 déc. 2018 07h30 HE | Source: BeyondSpring, Inc.

BeyondSpring Announces Phase 3 Study 105 of its Lead Asset Plinabulin for Chemotherapy-Induced Neutropenia Meets Primary Endpoint at Interim Analysis

NEW YORK, Dec. 06, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the...
04 déc. 2018 12h35 HE | Source: BeyondSpring, Inc.

Data for BeyondSpring’s Lead Asset, Plinabulin, for Chemotherapy-Induced Neutropenia (CIN) Prevention Shows Differentiated Profile Compared with G-CSF and Adds Additional Protection to G-CSF

Plinabulin monotherapy is an equally effective single-dose-per cycle agent as pegfilgrastim, but with minimal bone pain vs. pegfilgrastim in intermediate neutropenic risk CINPlinabulin and...
27 nov. 2018 07h00 HE | Source: BeyondSpring, Inc.

Plinabulin Newly Granted Patent Covering Method of Use in Prevention of Neutropenia

NEW YORK, Nov. 27, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the...
08 nov. 2018 07h30 HE | Source: BeyondSpring, Inc.

Clinical Results for BeyondSpring’s Lead Asset, Plinabulin for the Prevention of Chemotherapy-Induced Neutropenia, Demonstrated Superior Immune Profile Compared to Neulasta®

Company to Present Latest Findings at 2018 Society for Immunotherapy of Cancer’s (SITC) Annual Meeting NEW YORK, Nov. 08, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global...
23 oct. 2018 07h00 HE | Source: BeyondSpring, Inc.

BeyondSpring Announces Top Line Positive Efficacy and Safety Data from Phase 2 Study 106 with Lead Asset, Plinabulin, for Chemotherapy-Induced Neutropenia Prevention

Plinabulin Significantly Reduced Grade 3/4 CIN and Bone Pain When Combined with Neulasta, Compared to Neulasta Monotherapy, in Breast Cancer Patients Receiving High-Risk TAC Chemotherapy Company to...
23 oct. 2018 07h00 HE | Source: BeyondSpring, Inc.

BeyondSpring’s Lead Asset, Plinabulin for the Prevention of Chemotherapy-Induced Neutropenia, Has the Potential to Positively Impact Tumor Microenvironment

Data Demonstrating Plinabulin’s Immune-Enhancing Potential Presented at European Society for Medical Oncology (ESMO) Congress NEW YORK, Oct. 23, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:...
23 oct. 2018 07h00 HE | Source: BeyondSpring, Inc.

Beyondspring Provides Operational Update and Second-Quarter 2018 Financial Results

- Reported Top Line Positive Efficacy and Safety Data from Phase 2 Study 106 Evaluating Plinabulin in Combination With Neulasta for Chemotherapy-Induced Neutropenia (CIN) Prevention - On Track to...
19 oct. 2018 07h00 HE | Source: BeyondSpring, Inc.

BeyondSpring to Host Second-Quarter 2018 Financial Results and Operational Update Conference Call on October 23, 2018

Dr. Douglas Blayney from Stanford University to Join to Discuss Recently Announced Clinical Data NEW YORK, Oct. 19, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global,...

Page précédente